Inspire Technologies Signs Agreement to Conduct Clinical Study of HYLA Blood Sensor

December 27, 2022

The agreement with Sheba Medical Center, 10th ranked hospital in the world, to be the first site for the HYLA Blood Sensor’s Clinical Study

Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW), a groundbreaking respiratory support technology company, announced today that it has signed an agreement to conduct a clinical study of the HYLA blood sensor with Sheba Medical Center in Israel. The clinical study, expected to commence in the first quarter of 2023, will be performed in an operating room setting in patients undergoing open heart surgery using a cardiopulmonary bypass machine (CPB). The study objective is to further evaluate the HYLA blood sensor’s capabilities to measure blood gases in a non-invasive and continuous manner. The study results are expected to have a significant contribution to the product’s development.

Sheba Medical Center is internationally known for its groundbreaking medical research, integrating basic research, translational research and clinical studies across a broad spectrum of medical disciplines. Over the years, together with the MedTech industry, Sheba Medical Center has been involved in the development of medical innovations, including therapeutic solutions, diagnostic tools, imaging modalities, drug delivery systems and medical devices.

“We believe that the agreement with Sheba Medical Center is a clear indication of a world’s top hospital’s interest in our core blood sensor technology. The HYLA blood sensor is designed for multiple hospital settings, both inside and outside the operating room, which we believe increases its potential commercial appeal as a standalone device. In the future, we intend to add it to Inspira’s systems including the INSPIRA™ ART, currently under development,” stated Inspira Technologies’ CEO, Dagi Ben-Noon.

“Sheba Medical Center focuses on quality clinical research programs of key medical advancements to improve patient outcomes worldwide. Inspira Technologies’ HYLA blood sensor technology has significant potential to make a meaningful impact on real-time patient monitoring,” commented Dr. Yigal Kassif, (Principal Investigator (PI)), a senior cardiac surgeon in the Cardiac Surgery department and the director of the ECMO program at Sheba Medical Center.

About the HYLA Blood Sensor Clinical Study

The clinical study will be conducted in the operating rooms within the Department of Cardiac Surgery at Sheba Medical Center, by Dr. Kassif.

The HYLA blood sensor is designed as a non-invasive blood sensor, intended to provide continuous blood parameter measurements in real-time, potentially alerting physicians of sudden changes in a patient’s specific key indicators and allowing them to intervene and treat patients at an earlier stage. Early medical intervention may improve patient outcomes, reduce complications, and reduce associated costs.

Significance to the INSPIRA ART System

The INSPIRA ART introduces a new mode of acute respiratory care by supporting a patient’s spontaneous breathing while they are awake and alert, potentially reducing the need for invasive mechanical ventilation.

The HYLA blood sensor as part of the INSPIRA ART system will allow for patient oxygenation while displaying continuous blood measurements in real-time. Medical teams’ patient monitoring capabilities will be empowered.

About Inspira Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical technology company in the respiratory treatment arena. The Company is researching and developing a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while minimizing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company’s products have not yet been tested or used in humans and have not been approved by any regulatory entity.

Published December 14 2022, CISION PR Newswire

Don't miss out.

Sign up our weekly newsletter for the latest updates on medical advances and humanitarian efforts of Israel.